GlassScriptPhysician profile
Steven A Winer
NPI 1194764126
$2,484.73
in general payments reported to CMS, 2019-2025
30 companies · $19.00 in 2025
The $19.00 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $916 · 2020: $351 · 2021: $155 · 2022: $557 · 2023: $487 · 2025: $19.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $506.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $506.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $334.67 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $287.23 | 2019-2023 | Farxiga |
| Amgen INC. | $241.91 | 2019-2023 | Evenity, Prolia |
| Abbvie INC. | $187.01 | 2021-2023 | Vraylar, Ubrelvy |
| Merck Sharp & Dohme LLC | $165.91 | 2019-2023 | Belsomra, Steglatro, Vaxneuvance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $160.07 | 2019-2023 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $128.19 | 2019-2023 | |
| Lilly USA, LLC | $124.60 | 2019-2025 | Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $121.19 | 2019-2023 | Shingrix, Arexvy |
| Pfizer INC. | $118.01 | 2019-2023 | |
| Novo Nordisk INC | $75.66 | 2021-2023 | Ozempic, Rybelsus |
| Almatica Pharma LLC | $68.41 | 2022 | |
| Idorsia Pharmaceuticals US INC | $60.13 | 2022-2023 | Quviviq |
| Neurocrine Biosciences, INC. | $44.18 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $43.27 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $39.37 | 2019-2023 | |
| Allergan, INC. | $38.30 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $38.29 | 2019-2023 | Livalo, Seglentis |
| Novartis Pharmaceuticals Corporation | $31.15 | 2019-2022 | |
| Boston Scientific Corporation | $20.42 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.88 | 2019 | |
| Blueprint Medicines Corporation | $19.22 | 2023 | Ayvakit |
| Bayer Healthcare Pharmaceuticals INC. | $19.07 | 2023 | |
| Seqirus USA INC | $17.00 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Bausch Health US, LLC | $15.75 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $15.00 | 2020 | |
| Hikma Pharmaceuticals USA | $13.65 | 2020 | |
| Ibsa Pharma INC. | $13.64 | 2022 | |
| Ucb, INC. | $12.58 | 2022 | |
| Arbor Pharmaceuticals, INC. | $10.97 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Winer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.